• Belinostat (PXD101): HDAC–Splicing Assay Logic

  2026-08-27

  Belinostat (PXD101) is examined here as more than a proliferation inhibitor: it is a chromatin perturbation tool for connecting histone acetylation with RNA splicing and DNA-repair phenotypes. The article translates recent HCC spliceosome findings into practical, carefully bounded assay strategies.

• BRD4770 Workflows for G9a Epigenetic Research

  2026-08-27

  BRD4770 is a research-focused G9a histone methyltransferase inhibitor for connecting H3K9 methylation changes with proliferation, senescence, and cell death. This workflow emphasizes formulation control, orthogonal readouts, and careful translation of findings from PANC-1 models to broader cancer biology.

• Valemetostat for Reproducible EZH2 Assays

  2026-08-26

  This scenario-based guide explains how Valemetostat (SKU BA4816) can support reproducible lymphoma cell viability and epigenetic assays. It covers mechanism, formulation, protocol design, data interpretation, and practical supplier-selection criteria without confusing biochemical potency with cellular response.

• RG108 DNA Methyltransferase Inhibitor Workflow

  2026-08-26

  RG108 is a non-nucleosidic DNA methyltransferase inhibitor for testing demethylation, tumor suppressor gene reactivation, and epigenetic reprogramming without covalent enzyme trapping. This practical guide connects cell-based dosing, stem-cell applications, and pharmacokinetic assay design with troubleshooting steps for reproducible results.

• Romidepsin (FK228): Proteomics-Guided Assays

  2026-08-25

  Romidepsin and FK228 are powerful tools for studying class I HDAC biology, chromatin accessibility, cell-cycle control, and apoptosis. This article shows how multidimensional proteomics can improve target-engagement assays while separating evidence established for Romidepsin from hypotheses inspired by recent RFC4–Notch research.

• T0070907: Selective PPARγ Antagonist

  2026-08-25

  T0070907 is a covalent, selective PPARγ antagonist with reported IC50 and Ki values of 1 nM. It is used to study PPARγ signaling pathway inhibition, adipogenesis inhibition, transcriptional repression, and cell-cycle responses in cellular research.

• Thioguanine Sensitivity in Relapsed Childhood ALL

  2026-08-24

  This study examined whether immunophenotypic lineage predicts ex vivo drug resistance in childhood acute lymphoblastic leukaemia at relapse. Its central finding was that relapsed T-cell ALL was more sensitive to thiopurines, including thioguanine, but this pattern did not account for the clinically poorer prognosis of T-cell disease.

• Shh–Fgf Signaling in Guinea Pig Penile Development

  2026-08-24

  Wang and Zheng identify species-specific differences in Shh, Fgf10, and Fgfr2 expression as a mechanistic basis for why guinea pigs form an open urethral groove while mice do not. By combining comparative expression profiling with organ culture perturbations, the study provides a useful framework for interpreting epithelial remodeling and preputial development across mammalian models.

• METTL14–DHRS4-AS1 Axis in Ulcerative Colitis

  2026-08-23

  The reference study identifies an m6A-dependent METTL14–DHRS4-AS1/miR-206/A3AR pathway that limits epithelial inflammatory injury in ulcerative colitis models. Its combination of cell-based perturbation, molecular mechanism testing, and DSS-induced murine colitis connects RNA methylation to NF-κB activity, apoptosis, and tissue damage, while also highlighting important limits on causal and clinical interpretation.

• SP2509: LSD1 Antagonist Workflows for AML Research

  2026-08-22

  SP2509 enables mechanism-led studies of LSD1 inhibition, linking H3K4 methylation changes with tumor-suppressor activation, apoptosis, and differentiation in acute myeloid leukemia models. This guide translates the compound into practical dose-response, chromatin, phenotypic, and combination workflows while clarifying formulation limits and interpretation risks.

• GSK J4 HCl: JMJD3 Workflow Guide

  2026-08-22

  GSK J4 HCl enables cell-based testing of JMJD3-linked H3K27 demethylation in inflammatory, chromatin, and cancer workflows. This guide connects practical dosing, chromatin readouts, and troubleshooting to the CXCL10 methylation findings reported in human decidual models.

• Valemetostat in Reliable Cell Assays

  2026-08-21

  Learn how Valemetostat (DS-3201; SKU BA4816) can support better-controlled EZH2-focused cell viability and proliferation studies. This scenario-based guide covers formulation, dose interpretation, protocol handling, data comparison, and practical product selection.

• 3-Hydroxybutyrate (BHBA) in Ferroptosis Assays

  2026-08-20

  3-Hydroxybutyrate (BHBA) is both a ketone fuel and a signaling metabolite. This guide translates stroke research into a ferroptosis-aware assay framework that separates direct BHBA activity from whole-organism conditioning effects.

• Vancomycin hydrochloride in Resistance Workflows

  2026-08-20

  Vancomycin hydrochloride provides a mechanism-based Gram-positive control for susceptibility testing, resistance profiling, and Clostridium difficile infection studies. This guide combines practical reagent handling with a time-resolved modeling strategy inspired by recent resistance research.

• SGI-1027, DNMT1, and RB1 in Gastric Cancer

  2026-08-19

  A 2024 Discovery Medicine study links SGI-1027-mediated DNMT1 suppression with increased RB1 expression and reduced growth, migration, invasion, and metastasis of MKN45 gastric cancer cells. Its integrated cell and mouse experiments support a DNMT1–RB1 regulatory axis, while also highlighting the need for direct methylation and mechanistic validation.

3612 records 1/241 page Next 12345 下5页 Last page